Inglis Tiffany Eul Davis has filed 4 insider transactions across 1 company since October 2025.
Most recent transaction: a grant/award of 17437 shares of SERA PROGNOSTICS, INC. ($SERA) on March 12, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 12, 2026 | SERA PROGNOSTICS, INC. | $SERA | Inglis Tiffany Eul Davis | Chief Medical Officer | A | Class A Common Stock | 17437 | $0.00 | 92,437.0000 | 49,525,108 | 23.25% | 0.04% |
| March 12, 2026 | SERA PROGNOSTICS, INC. | $SERA | Inglis Tiffany Eul Davis | Chief Medical Officer | A | Stock Option (right to buy) | 27034 | $0.00 | 27,034.0000 | 49,525,108 | 9999.99% | 0.05% |
| Oct. 15, 2025 | SERA PROGNOSTICS, INC. | $SERA | Inglis Tiffany Eul Davis | Chief Medical Officer | A | Class A Common Stock | 75000 | $0.00 | 75,000.0000 | 49,525,108 | 9999.99% | 0.15% |
| Oct. 15, 2025 | SERA PROGNOSTICS, INC. | $SERA | Inglis Tiffany Eul Davis | Chief Medical Officer | A | Stock Option (right to buy) | 107000 | $0.00 | 107,000.0000 | 49,525,108 | 9999.99% | 0.22% |